Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Candice Riggeal

Neurology Jacksonville, FL Doctor of Osteopathy

NPI 1316104722 CMS profile 196120

841 Prudential Dr 10Th Floor, Jacksonville, FL 32207

Open in the dashboard

General payments

$10,203

458 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Candice Riggeal of Jacksonville, FL is reported in the CMS Open Payments database as having received $10,203 across 458 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,170 24
2024 General $808 25
2023 General $1,269 45
2022 General $1,852 73
2021 General $2,235 130
2020 General $992 67
2019 General $1,877 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Candice Riggeal
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Candice Riggeal were reported at $1,170. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Candice Riggeal Neurology median Middle half National median
2019 $1,877 $474 $118–$2,177 $163
2020 $992 $367 $82–$2,309 $114
2021 $2,235 $438 $104–$2,547 $132
2022 $1,852 $442 $103–$2,388 $149
2023 $1,269 $464 $119–$2,312 $160
2024 $808 $468 $119–$2,323 $164
2025 $1,170 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. SK Life Science, Inc. $1,203 37 payments
  2. Amgen Inc. $1,021 42 payments
  3. Teva Pharmaceuticals USA, Inc. $952 76 payments
  4. UCB, Inc. $818 20 payments
  5. Greenwich Biosciences, Inc. $609 12 payments
  6. Novartis Pharmaceuticals Corporation $503 31 payments
  7. Jazz Pharmaceuticals Inc. $445 19 payments
  8. Argenx US, Inc. $407 9 payments
  9. Eisai Inc. $361 17 payments
  10. Genzyme Corporation $358 15 payments
  11. Other $3,525 180 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,128 454 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $75 4 payments
Products named General payments · program years 2019–2025
  1. AIMOVIG $1,235 59 payments
  2. Epidiolex $1,055 31 payments
  3. Briviact $545 16 payments
  4. AJOVY $521 47 payments
  5. XCOPRI $520 5 payments
  6. Fycompa $275 14 payments
  7. UBRELVY Neuroscience $264 31 payments
  8. VALTOCO $261 8 payments
  9. BRIUMVI $254 2 payments
  10. UBRELVY Neuroscience $231 25 payments
  11. Other $4,269 190 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$31,113

Medicare's payments for the services billed

Medicare patients

225

Average age 74

Services billed

298

118 women, 107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Ischemic heart disease 59%
Diabetes 55%
Chronic kidney disease 53%
Depression 50%
Heart failure 48%
Alzheimer's or dementia 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XCOPRI
  • SK Life Science, Inc. $122
$122 — —
VYVGART Hytrulo
  • ARGENX US, INC. $95
$95 — —
Briviact
  • UCB, Inc. $87
$87 — —
Leqembi
  • Eisai Inc. $86
$86 — —
EMGALITY
  • Lilly USA, LLC $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

458 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record